Press Release Details

View all news

Arcus Biosciences Announces Upcoming Presentations at the 2019 American Association for Cancer Research Annual Meeting

February 28, 2019

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced seven presentations at the 2019 American Association for Cancer Research (AACR) Annual Meeting being held March 29-April 3, 2019 in Atlanta, Georgia.

Details of Arcus’s Presentations are as follows:

ORAL PRESENTATION:

AB680 (small-molecule CD73 inhibitor)

Title: Development of potent and selective CD73 inhibitors: Discovery and characterization of AB680
Date and Time: Saturday,March 30, 2019, 9:30 AM - 9:55 AM
Location: Room A311

POSTER PRESENTATIONS:

AB928 (dual A 2a R/A 2b R antagonist)

Title: Methods for assessment of the “adenosine fingerprint” in clinical trials of AB928
Abstract Number: 3168
Date and Time: Tuesday, April 2, 2019, 8:00 AM - 12:00 PM
Location: Exhibit Hall B, Poster Section: 21, Poster Board Number: 21

Title: Altered pan-Ras pathway and activating mutations in EGFR result in elevated CD73 in multiple cancers
Abstract Number: 4980
Date and Time: Wednesday, April 3, 2019, 8:00 AM - 12:00 PM
Location: Exhibit Hall B, Poster Section: 24, Poster Board Number: 3

AB122 (anti-PD-1 antibody)

Title: Longitudinal monitoring of neoepitope-specific T cell repertoires in patient blood following cancer immunotherapy
Abstract Number: 4042
Date and Time: Tuesday, April 2, 2019, 1:00 PM - 5:00 PM
Location: Exhibit Hall B, Poster Section: 22, Poster Board Number: 5

Title: Receptor occupancy and neo-epitope specific T-cell repertoires in patients with solid tissue tumors following anti-PD-1 therapy
Abstract Number: 4100
Session Date and Time: Tuesday, April 2, 2019, 1:00 PM - 5:00 PM
Location: Exhibit Hall B, Poster Section: 24, Poster Board Number: 3

AB154 (anti-TIGIT antibody)

Title: Characterization of AB154, a humanized α-TIGIT antibody, for use in combination therapies
Abstract Number: 1557
Session Date and Time: Monday, April 1, 2019, 8:00 AM - 12:00 PM
Location: Exhibit Hall B, Poster Section: 25,Poster Board Number: 26

AB474 (arginase inhibitor)

Title: AB474, a potent orally bioavailable inhibitor of arginase, for the treatment of cancer
Abstract Number: 3862
Date and Time: Tuesday, April 2, 2019, 1:00 PM - 5:00 PM
Location: Exhibit Hall B, Poster Section: 12, Poster Board Number: 12

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies. Arcus has several programs targeting important immuno-oncology pathways, including a dual adenosine receptor antagonist, AB928, which is in a Phase 1/1b program to evaluate AB928 in combination with other agents in multiple tumor types, and an anti-PD-1 antibody, AB122, which is being evaluated in a Phase 1 trial and is being tested in combination with Arcus’s other product candidates. Arcus’s other programs include AB154, an anti-TIGIT antibody, which is in a Phase 1 trial to evaluate AB154 as monotherapy and in combination with AB122, and AB680, a small-molecule inhibitor of CD73, which is in a Phase 1 healthy volunteer study. Arcus has extensive in-house expertise in medicinal chemistry, immunology, biochemistry, pharmacology and structural biology. For more information about Arcus Biosciences, please visit www.arcusbio.com.

Source: Arcus Biosciences

Nicole Arndt
(510) 284-4728
narndt@arcusbio.com

Source: Arcus Biosciences, Inc.

Categories: Press Releases
View all news